Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
- 1 January 1999
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 35 (1), 54-59
- https://doi.org/10.1016/s0959-8049(98)00353-0
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.Journal of Clinical Oncology, 1996
- CPT-11 (Irinotecan) in the treatment of colorectal cancerEuropean Journal of Cancer, 1995
- Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinomaAnnals of Oncology, 1994
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.BMJ, 1993
- The chemotherapy of colon cancer can no longer be ignoredEuropean Journal of Cancer, 1993
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1992
- Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.Journal of Clinical Oncology, 1992
- Protracted Infusion of 5-FU with Weekly Low-Dose Cisplatin as Second-Line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed 5-FU MonotherapyCancer Investigation, 1991
- Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancerCancer, 1989